Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
出版年份 2020 全文链接
标题
Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
作者
关键词
-
出版物
Cancer Medicine
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-09-03
DOI
10.1002/cam4.3262
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
- (2019) Pier Luigi Zinzani et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
- (2019) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers
- (2018) Cédric Rossi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
- (2017) Abhishek D. Garg et al. OncoImmunology
- Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes
- (2016) C. Y. Cheah et al. ANNALS OF ONCOLOGY
- Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
- (2016) R. Chen et al. BLOOD
- Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
- (2016) Bruce D. Cheson et al. BLOOD
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
- (2011) E. Campo et al. BLOOD
- Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
- (2009) Alison J. Moskowitz et al. BRITISH JOURNAL OF HAEMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started